Replies to post #246240 on Avid Bioservices Inc (CDMO)

[biopharm]

Partner prior second look in Couch way too risky for big pharma x to let y grab what might be.

Does anyone think J and J said let's wait for more data on ibrutinib it's only in phase II and only been studied on less then 200 patient.
..
..

I agree MD and the sabotage and new knowledge Peregrine has discovered on how valuable the PS Targeting pipeline actually is...

I'm sure a deal can be made.

I wonder if a mid-size pharma steps up with less cash for Peregrine but offers an amazing deal like 3-5 shares of their stock for every 1 PPHM

Big Pharma can offer 1 for 1 shares and their market cap can double...but a mid-size offering 3..4..or 5 for 1 shares along with cash can probably increase their market cap multiples higher

Some big out of the box thinking can come out of this

[Couch]

Partner prior second look in Couch way too risky for big pharma x to let y grab what might be.

While that certainly is possible, I think a deal will be inked after the second look in. Call it a hunch and though certain BP's may move quickly that has not been the case here for whatever reason.

Guess we'll both be here to find out.

[Krakonos]

md1225 your message is not getting through.

I understand why you go to this effort of posting that link and so many times already.

After reading the first page, the reader is forced to register with his email address in order to continue reading and that's when your effort goes in vain, because many, including me, will not do that.

WHAT prevents you to post full text on this board?
Seeking Alpha rule?
Too bad.

Your "audience" is hampered by that.